Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.
Int J Gynecol CancerJun 16, 2026 (epub)
Pauline Corbaux, Benoit You, Iain McNeish et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis examined differences in chemosensitivity, measured by the ELIMination rate constant K, between patients with advanced serous ovarian cancer from Japanese and Western trials. Among 5884 women, those in the Japanese trial had a significantly higher K value (median 0.071 day -1 vs 0.056 day -1; p <.0001), indicating potential ethnic variations in chemotherapy efficacy.
Key findings
- Japanese patients had a higher median K value of 0.071 day -1 compared to 0.056 day -1 in Western patients (p <.0001).
- Favorable K was associated with improved progression-free survival (hazard ratio 0.59) in the Japanese cohort.
- Using an exploratory cut-off of 0.07 day -1, K was linked to a hazard ratio of 0.35 for progression-free survival (p <.0001).
- Overall survival improved with favorable K, showing a hazard ratio of 0.53 in the Japanese trial.
Why it matters
Understanding ethnic and geographical differences in chemotherapy response can inform personalized treatment strategies for ovarian cancer, potentially improving patient outcomes based on chemosensitivity assessments.